Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

NCT07093294 · clinicaltrials.gov ↗
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

The Third Xiangya Hospital of Central South University

Collaborators